glp-1 kidney outcomes news receptor agonists and next-generation metabolic hormone therapies in chronic disease GLP-1 and the kidney: from

In the context of diabetes models, it may contribute to heart attack, impaired wound healing, stroke, and kidney damage

In some embodiments, therapeutically acceptable otic formulations are: The formulations disclosed herein alternatively encompass an otoprotectant agent in addition to the at least one active agent and/or excipients, including but not limited to such agents as antioxidants, alpha lipoic acid, calcium, fosfomycin or iron chelators, to counteract potential ototoxic effects that may arise from the use of specific therapeutic agents or excipients, diluents or carriers

B.DemirE.CetinelS

Moderate adverse effects include dizziness, mild increased heart rate, infections, headaches, and indigestion

It argues that because generics of liraglutide are already available specifically, Teva's authorised generic version of the drug, which launched in the middle of last year there is "no liraglutide attribute that must be addressed by compounding." Moreover, Novo Nordisk also claims that it is difficult to manufacture liraglutide and "even small changes in the manufacturing process of liraglutide can substantially affect its chemical and physical stability, as well as its impurity profile," and this means that there could be safety concerns with compounding

& Tenenbaum, A